Diabetes pill tested as shield against deadly liver damage
NCT ID NCT06364930
Summary
This 5-year study is testing if a common diabetes medication, dapagliflozin, can prevent serious liver complications like cancer and liver failure in people who have both chronic hepatitis B and diabetes. About 412 participants will be randomly assigned to take either the real drug or a placebo pill daily for up to five years. The main goal is to see if the drug reduces the risk of liver cancer and other severe liver problems in this high-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.